Focal therapy study for prostate cancer in Asia
Part of Cancer, Kidney & urinary clinical trials.
This study tests a targeted treatment for prostate cancer that aims to treat only the cancer while sparing healthy tissue. It may be an option for men with low to medium risk prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer.
- Your Gleason score (a measure of cancer aggressiveness) is 8 or lower.
- Your total cancer volume is small (up to 1.5 ml for two spots, or up to 3 ml for one spot).
- Your PSA level is 15 or lower.
- Your cancer has not spread outside the prostate (stage T2c or lower).
- Your overall health is good (ASA score 2 or less, meaning no severe health problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether targeting only the visible cancer spots on MRI (focal therapy) works as well as treating the whole prostate, for men with small, moderate-risk prostate cancer that hasn't spread.
This study is tracking men who choose focal therapy (a targeted treatment) for their localized prostate cancer. It aims to learn how well this treatment works and how it affects quality of life.
This registry tracks men with early-stage prostate cancer who choose focal therapy—a targeted treatment that destroys only the cancer area while preserving healthy prostate tissue. The study helps doctors understand how well this approach works and its safety.
This trial tests a gentler treatment called focal therapy that targets only the part of the prostate with cancer. It's for men whose prostate cancer has a Gleason score of 7, low PSA, and hasn't spread outside the prostate.
This study tests a new way to treat prostate cancer that is not visible on MRI but is detected by a special PET scan. The treatment is a focal therapy that targets only the cancer while sparing healthy tissue, and it aims to control the cancer with fewer side effects.
This study looks at outcomes after “focal therapy,” a type of treatment that targets only part of the prostate, for people with newly diagnosed or returning prostate cancer. It may help researchers understand how well this targeted approach works and for whom.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.